A number of firms have modified their ratings and price targets on shares of Bristol Myers Squibb (NYSE: BMY) recently:
- 11/16/2026 – Bristol Myers Squibb had its “buy (b-)” rating reaffirmed by Weiss Ratings.
- 10/30/2026 – Bristol Myers Squibb had its “buy” rating reaffirmed by Bank of America.
- 10/30/2026 – Bristol Myers Squibb was given a new $70.00 price target by Truist Financial.
- 10/30/2026 – Bristol Myers Squibb had its price target lowered by Morgan Stanley from $41.00 to $40.00. They now have an “underweight” rating on the stock.
- 10/26/2026 – Bristol Myers Squibb had its price target lowered by Piper Sandler from $82.00 to $78.00. They now have an “overweight” rating on the stock.
- 10/22/2026 – Bristol Myers Squibb was downgraded by Zacks Research from “strong-buy” to “hold”.
- 10/19/2026 – Bristol Myers Squibb had its “sector perform” rating reaffirmed by Royal Bank Of Canada.
- 10/16/2026 – Bristol Myers Squibb was upgraded by The Goldman Sachs Group from “hold” to “strong-buy”.
- 10/13/2026 – Bristol Myers Squibb had its “market perform” rating reaffirmed by Sanford C. Bernstein.
- 10/13/2026 – Bristol Myers Squibb had its price target lowered by Wells Fargo & Company from $65.00 to $60.00. They now have an “equal weight” rating on the stock.
- 10/12/2026 – Bristol Myers Squibb had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $76.00 price target on the stock.
- 10/12/2026 – Bristol Myers Squibb had its “market perform” rating reaffirmed by William Blair.
- 10/9/2026 – Bristol Myers Squibb had its price target lowered by Bank of America from $71.00 to $66.00.
- 10/8/2026 – Bristol Myers Squibb had its price target raised by Rothschild & Co Redburn from $51.00 to $53.00. They now have a “neutral” rating on the stock.
- 10/8/2026 – Bristol Myers Squibb had its price target lowered by Cantor Fitzgerald from $59.00 to $53.00. They now have a “neutral” rating on the stock.
- 10/7/2026 – Bristol Myers Squibb had its “underweight” rating reaffirmed by Morgan Stanley. They now have a $41.00 price target on the stock, up from $40.00.
- 10/5/2026 – Bristol Myers Squibb was downgraded by Leerink Partners from “outperform” to “market perform”. They now have a $59.00 price target on the stock, down from $73.00.
- 9/23/2026 – Bristol Myers Squibb had its “neutral” rating reaffirmed by The Goldman Sachs Group. They now have a $63.00 price target on the stock, up from $61.00.
- 9/23/2026 – Bristol Myers Squibb was upgraded by Zacks Research from “hold” to “strong-buy”.
Bristol Myers Squibb Stock Down 2.1%
Shares of Bristol Myers Squibb stock traded down $1.23 during trading on Thursday, reaching $58.33. 13,672,941 shares of the company traded hands, compared to its average volume of 11,934,425. The company has a 50 day moving average price of $61.65 and a 200-day moving average price of $60.41. Bristol Myers Squibb Company has a 1-year low of $45.26 and a 1-year high of $68.64. The firm has a market capitalization of $119.23 billion, a PE ratio of 12.93, a P/E/G ratio of 0.32 and a beta of 0.20. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The company had revenue of $13.07 billion for the quarter, compared to analysts’ expectations of $12.72 billion. During the same quarter in the prior year, the firm earned $1.63 EPS. The business’s revenue was up 6.9% on a year-over-year basis. As a group, equities research analysts expect that Bristol Myers Squibb Company will post 6.46 earnings per share for the current fiscal year.
Bristol Myers Squibb Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.88%.
Insider Buying and Selling
In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Julia Haller sold 3,800 shares of the stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the sale, the director directly owned 30,279 shares of the company’s stock, valued at $1,916,963.49. The trade was a 11.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.05% of the company’s stock.
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Featured Stories
- Five stocks we like better than Bristol Myers Squibb
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Bristol Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.
